Fig. 3

Patients were stratified by Cyclin D1 levels (0.46nmol/g threshold), using “survminer” to assess prognosis. Cyclin D1-high patients (>0.46nmol/g) showed significantly better survival outcomes (p = 0.017), with longer median survival and higher survival rates than Cyclin D1-low (≤ 0.46nmol/g) patients